AU2002362098A1 - Methods of therapy for non-hodgkin's lymphoma - Google Patents

Methods of therapy for non-hodgkin's lymphoma

Info

Publication number
AU2002362098A1
AU2002362098A1 AU2002362098A AU2002362098A AU2002362098A1 AU 2002362098 A1 AU2002362098 A1 AU 2002362098A1 AU 2002362098 A AU2002362098 A AU 2002362098A AU 2002362098 A AU2002362098 A AU 2002362098A AU 2002362098 A1 AU2002362098 A1 AU 2002362098A1
Authority
AU
Australia
Prior art keywords
hodgkin
lymphoma
therapy
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002362098A
Other versions
AU2002362098A8 (en
Inventor
Deborah Hurst
Sandra Milan
Maurice J. Wolin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/293,664 external-priority patent/US20030185796A1/en
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2002362098A8 publication Critical patent/AU2002362098A8/en
Publication of AU2002362098A1 publication Critical patent/AU2002362098A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
AU2002362098A 2001-12-07 2002-12-06 Methods of therapy for non-hodgkin's lymphoma Abandoned AU2002362098A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1796801A 2001-12-07 2001-12-07
US10/017,968 2001-12-07
US10/293,664 2002-11-12
US10/293,664 US20030185796A1 (en) 2000-03-24 2002-11-12 Methods of therapy for non-hodgkin's lymphoma
PCT/US2002/039253 WO2003049694A2 (en) 2001-12-07 2002-12-06 Methods of therapy for non-hodgkin's lymphoma

Publications (2)

Publication Number Publication Date
AU2002362098A8 AU2002362098A8 (en) 2003-06-23
AU2002362098A1 true AU2002362098A1 (en) 2003-06-23

Family

ID=26690566

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002362098A Abandoned AU2002362098A1 (en) 2001-12-07 2002-12-06 Methods of therapy for non-hodgkin's lymphoma

Country Status (5)

Country Link
EP (1) EP1463524A4 (en)
JP (1) JP2005538034A (en)
AU (1) AU2002362098A1 (en)
CA (1) CA2469045A1 (en)
WO (1) WO2003049694A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR042485A1 (en) 2002-12-16 2005-06-22 Genentech Inc HUMANIZED ANTIBODY THAT JOINS THE HUMAN CD20
CA2526402A1 (en) 2003-06-05 2005-01-20 Genentech, Inc. Blys antagonists and uses thereof
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
KR20070001931A (en) * 2003-12-22 2007-01-04 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
PL1758610T3 (en) 2004-05-20 2012-11-30 Zymogenetics Inc Methods of treating cancer using il-21 and monoclonal antibody therapy
BRPI0510915A (en) 2004-06-04 2007-11-13 Genentech Inc Method for treating multiple sclerosis and manufactured article
KR20070108402A (en) * 2005-02-15 2007-11-09 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 Methods for treating lymphomas using a combination of a chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
ES2751022T3 (en) 2007-07-09 2020-03-30 Genentech Inc Prevention of reduction of disulfide bonds during recombinant production of polypeptides
DK2233149T3 (en) 2007-10-16 2016-05-17 Zymogenetics Inc COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
ATE548052T1 (en) * 2008-01-17 2012-03-15 Philogen Spa COMBINATION OF AN ANTI-EDB-FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN AND A B-CELL-BINDING MOLECULE, B-CELL PRECURSORS AND/OR THEIR CARCINOGENIC ANTEPANT
AR073295A1 (en) 2008-09-16 2010-10-28 Genentech Inc METHODS TO TREAT PROGRESSIVE MULTIPLE SCLEROSIS. MANUFACTURING ARTICLE.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
LT2464725T (en) 2009-08-11 2020-06-10 F. Hoffmann-La Roche Ag Production of proteins in glutamine-free cell culture media
RU2573994C2 (en) 2010-02-10 2016-01-27 Иммьюноджен, Инк Anti-cd20 antibodies and thereof application
CN113999312A (en) 2015-06-24 2022-02-01 豪夫迈·罗氏有限公司 Anti-transferrin receptor antibodies with tailored affinity
AU2016333512B2 (en) 2015-10-02 2022-11-17 F. Hoffmann-La Roche Ag Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
CN115521913B (en) * 2022-02-22 2023-07-25 北京景达生物科技有限公司 NK cells and CD20, CD38 and Her2 antibodies combined application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009427A1 (en) * 2000-03-24 2002-01-24 Wolin Maurice J. Methods of therapy for non-hodgkin's lymphoma

Also Published As

Publication number Publication date
WO2003049694A3 (en) 2003-11-06
AU2002362098A8 (en) 2003-06-23
EP1463524A2 (en) 2004-10-06
WO2003049694A2 (en) 2003-06-19
EP1463524A4 (en) 2005-02-09
CA2469045A1 (en) 2003-06-19
JP2005538034A (en) 2005-12-15

Similar Documents

Publication Publication Date Title
AU2002362098A1 (en) Methods of therapy for non-hodgkin's lymphoma
AU2002257936A1 (en) Methods of well treatment
AU2001247737A1 (en) Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2
AU2002348135A1 (en) Methods for the treatment of addiction
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2003225160A1 (en) "biosensor for dialysis therapy"
AU2002345612A1 (en) Ultrasound-fluoroscopic seed therapy system and method
AU2882299A (en) Anti-asthma therapy
AU3891299A (en) Combination therapy for treatment of depression
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU3784999A (en) Methods for treatment of pain
AU2003237657A1 (en) Means and methods for improved treatment using "setrones"
AU2002256053A1 (en) Novel bgp compounds for therapy and diagnosis and methods for using same
AU5342099A (en) Dental treatment methods
AUPR731901A0 (en) Method of treatment
AU4598400A (en) Method of treatment
AU2001253560A1 (en) Methods of treatment
AU2002232563A1 (en) Compounds for therapy and diagnosis and methods for using same
WO2004039333A9 (en) ANTIGENIC gp 100 COMPOUNDS FOR THERAPY AND DIAGNOSIS AND METHODS FOR USING SAME
AU2002337442A1 (en) Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia
AU2002367463A1 (en) NOVEL p53BP2 COMPOUNDS FOR THERAPY AND DIAGNOSIS AND METHODS FOR USING SAME
AU2002324193A1 (en) Therapeutic insert and therapeutic method
AU2001255255A1 (en) Therapeutic compounds and methods
AU2002324724A1 (en) Compositions and methods for the treatment of cancer
AU2002257731A1 (en) Method of well treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase